Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: A systematic review

Annals of Internal Medicine

Volumn 165, Issue 8, 2016, Pages 565-574

  Chingcuanco, Francine ^a   Segal, Jodi B ^a   Kim, Seoyoung C ^b   Alexander, G Caleb ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; BIOSIMILAR AGENT; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLERGIC REACTION; BIOEQUIVALENCE; CLINICAL OUTCOME; COCHRANE LIBRARY; COHORT ANALYSIS; COUGHING; CROSS REACTION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EMBASE; EUROPEAN MEDICINES AGENCY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LATENT TUBERCULOSIS; MEDLINE; OBSERVATIONAL STUDY; OROPHARYNX PAIN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SIDE EFFECT; SYSTEMATIC REVIEW; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; WORLD HEALTH ORGANIZATION; ANTAGONISTS AND INHIBITORS; ANTIBODY PRODUCTION; ARTHRITIS, RHEUMATOID; INFLAMMATORY BOWEL DISEASES; THERAPEUTIC EQUIVALENCE;

ANTIBODY FORMATION; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; HUMANS; INFLAMMATORY BOWEL DISEASES; THERAPEUTIC EQUIVALENCY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84992623566     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0428     Document Type: Review

References (63)

1. IMS Institute for Healthcare Informatics. The global use of medicines: outlook through 2017. November 2013. Accessed at www.imshealth.com/en/thought-leadership/ims-institute/reports/global-use-of-medicines-outlook-through-2017 on 4 July 2016.
2. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008;19:411-9. [PMID: 17872902]
3. Kuhlmann M, Covic A. The protein science of biosimilars. Nephrol Dial Transplant. 2006;21 Suppl 5:v4-8. [PMID: 16959791]
4. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 18 December 2014. Accessed at www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2015/01/WC500180219.pdf on 29 October 2015.
5. U.S. Food and Drug Administration. Information for consumers (biosimilars). 27 August 2015. Accessed at www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedand Approved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm on 29 October 2015.
6. U.S. Food and Drug Administration. Information on tumor necrosis factor (TNF) blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi). 8 July 2015. Accessed at www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109340.htm on 29 October 2015.
7. Philippidis A. The top 25 best-selling drugs of 2014. 23 February 2015. Accessed at www.genengnews.com/insight-and-intelligenceand153/the-top-25-best-selling-drugs-of-2014/77900383 on 30 October 2015.
8. U.S. Food and Drug Administration. FDA approves Inflectra, a biosimilar to Remicade [press release]. Silver Spring, MD: U.S. Food and Drug Administration; 2016.
9. Celltrion Healthcare. Remsima. 2016. Accessed at www.celltrion healthcare.com/02-products/products01.asp on 17 February 2016.
10. Hanwha Chemical. Biopharmaceuticals. 2016. Accessed at http://hcc.hanwha.com/eng/business/bus-bio.jsp on 17 February 2016.
11. Samsung Bioepis. News room. September 2015. Accessed at www.samsungbioepis.com/newsroom2/newsroom-9.html on 17 February 2016.
12. Business Wire. Samsung Bioepis' RENFLEXIS infliximab biosimilar receives regulatory approval in Korea. 4 December 2015. Accessed at www.businesswire.com/news/home/20151204005228/en/Samsung-Bioepis-RENFLEXIS%C2%AE-Infliximab-Biosimilar-Receives-Regulatory on 20 May 2016.
13. Epirus Biopharmaceuticals. BOW015 (infliximab). 2015. Accessed at www.epirusbiopharma.com/programs/bow015-infliximab.php on 4 July 2016.
14. Cadila Healthcare. Adalimumab. 2016. Accessed at http://exemptia.com/adalimumab on 17 February 2016.
15. CiplaMed. ETACEPT injection. November 2013. Accessed at www.ciplamed.com/content/etacept-injection on 20 May 2016.
16. Quantia. Reading the signs: a roadmap for engaging physicians in the biosimilars discussion. August 2015. Accessed at http://cdn2.hubspot.net/hubfs/436920/Whitepaper-Quantia-Reading-the-Signs-August-2015.pdf on 8 November 2015.
17. Derbyshire M. ECCO 2013 survey highlights lack of confidence in biosimilars. Generics and Biosimilars Initiative Journal. 2014;3: 154.
18. Zelenetz AD, Ahmed I, Braud EL, Cross JD, Davenport-Ennis N, Dickinson BD, et al. NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011;9 Suppl 4:S1-22. [PMID: 21976013]
19. PROSPERO: international prospective register of systematic reviews. 2016. Accessed at www.crd.york.ac.uk/PROSPERO on 8 April 2016.
20. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68 Suppl 2:ii1-44. [PMID: 19433414] Doi: 10.1136/ard.2008.104018
21. American College of Rheumatology. ACR-endorsed criteria for rheumatic diseases. 2016. Accessed at www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria on 20 May 2016.
22. Higgins JP, Altman DG, Gøtzsche PC, Jü ni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. [PMID: 22008217] Doi: 10.1136/bmj.d5928
23. Wells GA, Shea B, O'Connell D, Peterson JEA, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. Ottawa Hospital Research Institute. 2011. Accessed at www.ohri.ca/programs/clinical-epidemiology/oxford.asp on 27 May 2016.
24. Gu N, Yi S, Kim TE, Kim J, Shin SG, Jang IJ, et al. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. ClinTher.2011;33:2029-37.[PMID:22088414]Doi: 10.1016/j.clinthera.2011.10.022
25. Yi S, Kim SE, Park MK, Yoon SH, Cho JY, Lim KS, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (EnbrelR): a double-blind, single-dose, cross-over study in healthy volunteers. BioDrugs. 2012;26:177-84. [PMID: 22515513] Doi: 10.2165/11631860-000000000-00000
26. Park W, Lee SJ, Yun J, Yoo DH. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EUapproved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, phase I study. Expert Rev Clin Immunol. 2015;11 Suppl 1:S25-31. [PMID: 26395834] Doi: 10.1586/1744666X.2015.1090311
27. Shin D, Kim Y, Kim YS, Kö rnicke T, Fuhr R. A randomized, phase I pharmacokinetic study comparing SB2 and infliximab reference product (RemicadeR) in healthy subjects. BioDrugs. 2015;29:381-8. [PMID: 26577771] Doi: 10.1007/s40259-015-0150-5
28. Lambert J, Wyand M, Lassen C, Shneyer L, Thomson E, Knight A, et al. Bioavailability, safety and immunogenicity of biosimilar infliximab (BOW015) compared to reference infliximab. Int J Clin Pharmacol Ther. 2016;54:315-22. [PMID: 26952037] Doi: 10.5414/CP202530
29. Lee Y, Shin D, Kim Y, Kang J, Gauliard A, Fuhr R. A randomised phase l pharmacokinetic study comparing SB4 and etanercept reference product (EnbrelR) in healthy subjects. Br J Clin Pharmacol. 2016. [PMID: 26972584] Doi: 10.1111/bcp.12929
30. Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605-12. [PMID: 23687259] Doi: 10.1136/annrheumdis-2012-203091
31. Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patientreported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25. [PMID: 26795209] Doi: 10.1186/s13075-016-0930-4
32. Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25:817-24. [PMID: 25736355] Doi: 10.3109/14397595.2015.1022297
33. Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72:1613-20. [PMID: 23687260] Doi: 10.1136/annrheumdis-2012-203090
34. Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2015;18:82. [PMID: 27038608] Doi: 10.1186/s13075-016-0981-6
35. Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, Baranauskaite A, et al. A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015. [PMID: 26318384] Doi: 10.1136/annrheumdis-2015-207764
36. Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015. [PMID: 26150601] Doi: 10.1136/annrheumdis-2015-207588
37. Jani RH, Gupta R, Bhatia G, Rathi G, Ashok Kumar P, Sharma R, et al. A prospective, randomized, double-blind, multicentre, parallelgroup, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis. Int J Rheum Dis. 2015. [PMID: 26176644] Doi: 10.1111/1756-185X.12711
38. Bae SC, Kim J, Choe JY, Park W, Lee SH, Park YB, et al; HERA Study Investigators. A phase III, multicentre, randomised, doubleblind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study. Ann Rheum Dis. 2016. [PMID: 26905864] Doi: 10.1136/annrheumdis-2015-207613
39. Ben-Horin S, Yavzori M, Benhar I, Fudim E, Picard O, Ungar B, et al. Cross-immunogenicity: antibodies to infliximab in Remicadetreated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65:1132-8. [PMID: 25897019] Doi: 10.1136/gutjnl-2015-309290
40. Ruiz-Argü ello MB, Maguregui A, Ruiz Del Agua A, Pascual-Salcedo D, Martínez-Feito A, Jurado T, et al. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars. Ann Rheum Dis. 2016. [PMID: 26965981] Doi: 10.1136/annrheumdis-2015-208684
41. Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60: 951-6. [PMID: 25326115] Doi: 10.1007/s10620-014-3392-z
42. Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705-12. [PMID: 25974251] Doi: 10.1111/jgh.12997
43. Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15: 1677-83. [PMID: 26549204] Doi: 10.1517/14712598.2015.1103733
44. Hlavaty T, Krajcovicova A, Sturdik I, Letkovsky J, Koller T, Toth J, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases-a one-year, single-centre retrospective study. Journal of Gastroenterology and Hepatology. 2016;70:27-36.
45. Torrent Pharma. Torrent Pharma forays into super specialty segment and launches Adfrar-biosimilar adalimumab [press release]. 12 January 2016. Accessed at www.torrentpharma.com/media-popup.php?mid=154 on 5 June 2016.
46. Coherus Biosciences. CHS-0214 etanercept biosimilar. 2016. Accessed at www.coherus.com/our-products/chs-0214 on 5 June 2016.
47. Amgen.FDA accepts Amgen's biosimilar biologics license application for ABP 501 [press release]. Thousand Oaks, CA: Amgen; 25 January 2016. Accessed at www.amgen.com/media/news-releases/2016/01/fda-accepts-amgens-biosimilar-biologics-license-application-for-abp-501 on 5 June 2016.
48. Janssen Biotech. Ankylosing spondylitis: Remicade (infliximab) efficacy. 21 July 2015. Accessed at www.remicade.com/hcp/ankylosing-spondylitis/efficacy on 4 December 2015.
49. Janssen Biotech. Rheumatoid arthritis: Remicade (infliximab) efficacy. 21 July 2015. Accessed at www.remicade.com/hcp/rheumatoid-arthritis/efficacy/signs-and-symptoms/rapid-response on 4 December 2015.
50. U.S. Food and Drug Administration. Reporting serious problems to FDA. 2 January 2016. Accessed at www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm on 5 June 2016.
51. Wadhwa M, Knezevic I, Kang HN, Thorpe R. Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility. Biologicals. 2015;43:298-306. [PMID: 26144595] Doi: 10.1016/j.biologicals.2015.06.004
52. Bond S. Comparing MSD electrochemiluminescent detection technology to traditional ELISA for clinical applications. Accessed at www.cambridgebiomedical.com/DesktopModules/Bring2mind/DMX/Download.aspx?Command=Core-Download&EntryId=2091 &PortalId=0&TabId=155 on 5 June 2016.
53. Matsushima S, Huang Y, Suzuki H, Nishino J, Lloyd P. Ethnic sensitivity assessment-pharmacokinetic comparability between Japanese and non-Japanese healthy subjects on selected mAbs. Expert Opin Drug Metab Toxicol. 2015;11:179-91. [PMID: 25519513] Doi: 10.1517/17425255.2015.990438
54. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor(TNF) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64 Suppl 4:iv2-14. [PMID: 16239380]
55. Dö rner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11:713-24. [PMID: 26282080] Doi: 10.1038/nrrheum.2015.110
56. Isaacs JD, Cutolo M, Keystone EC, Park W, Braun J. Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody. J Intern Med. 2016;279:41-59. [PMID: 26403380] Doi: 10.1111/joim.12432
57. Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42:1158-69. [PMID: 26365281] Doi: 10.1111/apt.13402
58. U.S. Food and Drug Administration. FDA briefing document Arthritis Advisory Committee Meeting February 09, 2016: BLA 125544 CT-P13, a proposed biosimilar to RemicadeR (infliximab). 2016. Accessed at www.fda.gov/downloads/advisorycommittees/committees meetingmaterials/drugs/arthritisadvisorycommittee/ucm484859.pdf on 15 May 2016.
59. Generics and Biosimilars Initiative. Extrapolation of indications in biosimilars: infliximab. 1 September 2015. Accessed at http://gabionline.net/Biosimilars/Research/Extrapolation-of-indications-in-biosimilars-infliximab on 30 October 2015.
60. European Medicines Agency. Assessment Report: Remsima. London: European Medicines Agency; 2013.
61. Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Urena S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2016. [PMID: 27117698] Doi: 10.1136/annrheumdis-2015-208783
62. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2016. [PMID: 27130908] Doi: 10.1136/annrheumdis-2015-208786
63. The NOR-SWITCH study (NOR-SWITCH). ClinicalTrials.gov: NCT02148640. Accessed at https://clinicaltrials.gov/ct2/show/NCT02148640 on 30 October 2015.